[go: up one dir, main page]

MX2018002543A - Compositions comprising urolithin compounds. - Google Patents

Compositions comprising urolithin compounds.

Info

Publication number
MX2018002543A
MX2018002543A MX2018002543A MX2018002543A MX2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A MX 2018002543 A MX2018002543 A MX 2018002543A
Authority
MX
Mexico
Prior art keywords
compositions
urolithin
urolithin compounds
compounds
provides
Prior art date
Application number
MX2018002543A
Other languages
Spanish (es)
Inventor
Blanco-Bose William
Andreux Penelope
Rinsch Christopher
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of MX2018002543A publication Critical patent/MX2018002543A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions,such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
MX2018002543A 2015-08-28 2016-08-26 Compositions comprising urolithin compounds. MX2018002543A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1515387.7A GB201515387D0 (en) 2015-08-28 2015-08-28 Compositions
PCT/EP2016/070255 WO2017036992A1 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds

Publications (1)

Publication Number Publication Date
MX2018002543A true MX2018002543A (en) 2018-06-15

Family

ID=54326542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002543A MX2018002543A (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds.

Country Status (15)

Country Link
US (4) US10695320B2 (en)
EP (1) EP3340977B1 (en)
JP (3) JP7227003B2 (en)
KR (2) KR102822365B1 (en)
CN (1) CN108289879A (en)
AU (1) AU2016314987B2 (en)
BR (1) BR112018003745B1 (en)
CA (1) CA2996724C (en)
ES (1) ES2936723T3 (en)
GB (1) GB201515387D0 (en)
MX (1) MX2018002543A (en)
PT (1) PT3340977T (en)
RU (1) RU2754761C2 (en)
SG (1) SG10202001793PA (en)
WO (1) WO2017036992A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
EP4553071A3 (en) * 2017-03-08 2025-07-23 Amazentis SA Methods for improving mitophagy in subjects
WO2019222146A1 (en) 2018-05-15 2019-11-21 University Of Louisville Research Foundation, Inc. Urolithin a and derivatives thereof for use in therapy
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
AU2021346837A1 (en) 2020-09-25 2023-03-02 Société des Produits Nestlé S. A. Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
JP7541673B2 (en) * 2020-11-30 2024-08-29 国立研究開発法人産業技術総合研究所 Anti-inflammatory agent for muscular dystrophy, composition for total parenteral nutrition for anti-inflammation in muscular dystrophy, and food composition for anti-inflammation in muscular dystrophy
KR102623664B1 (en) 2020-12-10 2024-01-12 서울대학교산학협력단 Composition and treatment method for diabetic Alzheimer's disease using urolitin A
CN117015530A (en) 2021-01-27 2023-11-07 范徳利亚股份公司 Urolithin derivatives and methods of use
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
CN113813255B (en) * 2021-10-20 2023-09-01 山东大学 Application of urolithin A and derivatives thereof in tumor immunotherapy
JPWO2023199908A1 (en) * 2022-04-11 2023-10-19
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
EP4642448A1 (en) * 2022-12-27 2025-11-05 Indian Institute of Science A method for the treatment of epilepsy
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
EP4555997A1 (en) * 2023-11-15 2025-05-21 Science4Beauty Sp. z o.o. Water-soluble composition comprising urolithin
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
KR20250158913A (en) 2024-04-30 2025-11-07 주식회사 파이안바이오테크놀로지 Hair Loss Reliever Composition and Hair Growth Promoter Composition which containing Urolithin A
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3786447B2 (en) * 1995-03-31 2006-06-14 エーザイ株式会社 Preventive and therapeutic agent for hepatitis C
MEP18308A (en) 1996-03-26 2010-06-10 Lilly Co Eli Benzothiophenes, formulations containing same, and methods
WO1999053941A1 (en) * 1998-04-15 1999-10-28 Shionogi & Co., Ltd. Oral preparations containing trh derivatives
ES2301477T3 (en) 1999-02-22 2008-07-01 Merrion Research I Limited SOLID ORAL DOSAGE FORM CONTAINING A POTENTIATOR.
US6623734B2 (en) * 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
JP5147239B2 (en) 2004-09-29 2013-02-20 三栄源エフ・エフ・アイ株式会社 Coenzyme Q10-containing emulsion composition
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP2145904A1 (en) 2008-07-18 2010-01-20 Basf Se Method for enzyme-catalysed hydrolysis of polyacrylic acid esters and esterases to be used
ES2629131T3 (en) 2008-09-17 2017-08-07 Chiasma Inc. Pharmaceutical compositions and related delivery methods.
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
RU2015142279A (en) 2010-03-19 2018-12-28 Бостон Байомедикал, Инк. NEW COMPOUNDS AND COMPOSITIONS FOR TARGETING MALIGNANT STEM CELLS
KR101823706B1 (en) 2010-03-22 2018-01-30 인스틸로 게엠베하 Method and device for producing microparticles or nanoparticles
CA2796494A1 (en) 2010-04-20 2011-10-27 Cipla Limited Pharmaceutical composition
EA201390766A1 (en) 2010-11-24 2013-11-29 Экселиксис, Инк. PETROXAZEPINS AS PI3K / mTOR INHIBITORS AND METHODS FOR THEIR USE AND OBTAIN
JP2012111712A (en) 2010-11-25 2012-06-14 Toyo Capsule Kk Composition for oil vitamin c oral administration
SG191297A1 (en) * 2010-12-23 2013-07-31 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
JP2014501784A (en) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド Pharmaceutical composition of iron for oral administration
US20140079729A1 (en) * 2012-09-14 2014-03-20 Natreon, Inc. Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit
GB201323008D0 (en) * 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions

Also Published As

Publication number Publication date
US20180243261A1 (en) 2018-08-30
KR20240060826A (en) 2024-05-08
JP2025004129A (en) 2025-01-14
RU2754761C2 (en) 2021-09-07
US20200323818A1 (en) 2020-10-15
KR102660005B1 (en) 2024-04-22
GB201515387D0 (en) 2015-10-14
US10695320B2 (en) 2020-06-30
CA2996724A1 (en) 2017-03-09
EP3340977B1 (en) 2022-11-02
RU2018108136A (en) 2019-09-30
CN108289879A (en) 2018-07-17
US20220323407A1 (en) 2022-10-13
SG10202001793PA (en) 2020-04-29
HK1257500A1 (en) 2019-10-25
PT3340977T (en) 2023-01-31
BR112018003745A2 (en) 2018-09-25
US11337957B2 (en) 2022-05-24
AU2016314987B2 (en) 2021-07-08
RU2018108136A3 (en) 2020-01-31
CA2996724C (en) 2024-05-21
JP2018533618A (en) 2018-11-15
JP2022177130A (en) 2022-11-30
US11925616B2 (en) 2024-03-12
AU2016314987A1 (en) 2018-03-29
EP3340977A1 (en) 2018-07-04
ES2936723T3 (en) 2023-03-21
JP7227003B2 (en) 2023-02-21
BR112018003745B1 (en) 2023-11-07
KR20180037052A (en) 2018-04-10
US20240148690A1 (en) 2024-05-09
WO2017036992A1 (en) 2017-03-09
KR102822365B1 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
MX2018002543A (en) Compositions comprising urolithin compounds.
MX2018002546A (en) COMPOSITIONS THAT INCLUDE A UROLITINE COMPOUND.
SA517381819B1 (en) Immune modulation
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
MY187540A (en) Compounds active towards bromodomains
MD20170035A2 (en) Compositions and methods of use for treating matabolic disorders
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX2017009720A (en) Oligosaccharide compositions for use in nutritional compositions, and methods of producing thereof.
EP3102220C0 (en) SYNERGISTIC FOOD SUPPLEMENT COMPOSITIONS FOR THE PREVENTION, TREATMENT OR COMBAT OF INFLAMMATORY DISEASES
MX2017002489A (en) Human therapeutic agents.
HK1245658A1 (en) Nutritional composition useful in the treatment of ibd patients
PH12018500994A1 (en) Nutritional compositions containing butyrate and uses thereof
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
IL259183B (en) Food supplement and composition for treating the metabolic syndrome
WO2016080796A3 (en) Pharmaceutical composition, containing sesquiterpene compound, for preventing or treating stat3-mediated diseases, and use thereof
ZA201706915B (en) Methods and compositions for the treatment of cellulosic biomass and products produced thereby
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
TR201908639T4 (en) Saffron-based compositions for the prevention or treatment of degenerative eye disorders.
PH12016501838A1 (en) Compounds and their methods of use
ZA201802606B (en) Compositions for dental varnishes and methods of making and using same
PH12019550209A1 (en) A nutritional composition for use to enhance attention and/or reduce impulsivity
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
MY188896A (en) Methods and compositions for reducing digestive/absorptive rates and ratio of food/drinks or reducing a digestive solution
HK1255053A1 (en) Compositions and methods for inhibiting cancer stem cells
PL413830A1 (en) Lactoferrin with manganese ions complex, method for obtaining it, application of the complex and pharmaceutical composition containing the complex of lactoferrin and manganese ions